Brief: Adial Pharmaceuticals Completes Successful Eop2 FDA Meeting
06/08/2025 13:22
Aug 6 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS COMPLETES SUCCESSFUL EOP2 FDA MEETING ADIAL PHARMACEUTICALS INC - TO ADVANCE AD04 INTO PHASE 3 FOR ALCOHOL USE DISORDER Source text: ID:nGNX8xNhZn Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)